Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach

Affiliations

• ¹ University of Bern, Department of BioMedical Research, Bern, Switzerland. harpreet.mandhair@unibe.ch.
• ² Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. harpreet.mandhair@unibe.ch.
• ³ Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. harpreet.mandhair@unibe.ch.
• ⁴ University of Bern, Department of BioMedical Research, Bern, Switzerland.
• ⁵ Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
• ⁶ Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
• ⁷ Department of Biology, University of Fribourg, Fribourg, Switzerland.
• ⁸ Southampton NHIR/Cancer Research UK, Experimental Cancer Medicines Centre, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
• ⁹ Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
• ¹⁰ University of Bern, Department of BioMedical Research, Bern, Switzerland. urban.novak@insel.ch.
• ¹¹ Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. urban.novak@insel.ch.